FDA nixes Acomplia smoking indication but may approve drug for weight loss

Share this article:
The FDA declined approving Sanofi-Aventis’ highly anticipated Acomplia (rimonabant) for smoking cessation but may give a green light to the drug for weight loss, the French drugmaker said in a statement on Friday. The Sanofi statement said the FDA issued the manufacturer an “approvable” letter outlining what it must do to win approval of Acomplia for weight loss. Neither Sanofi nor the FDA disclosed the conditions that must be met before the agency will let the company sell Acomplia in the US. “Sanofi-Aventis will continue to work in close collaboration with the FDA,” the company's statement said.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.